Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (141-150 of 273) with videos related to

Pageof 28
Sort By:
Frontiers in Oncology|May 16, 2022
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: An Updated Database of 1023 Cases Brief ReportJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.
JTO Clinical and Research Reports|September 30, 2021
Biomarker Testing for People With Advanced Lung Cancer in EnglandJana B Adizie, Judith Tweedie, Aamir Khakwani, et al.
Cancers|January 26, 2024
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint BlockadeAndriani Charpidou, Grigorios Gerotziafas, Sanjay Popat, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
Targeted Oncology|January 18, 2023
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.
Plos One|October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatmentsAnna Minchom, Parames Thavasu, Zai Ahmad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2016
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesMartin Schuler, Yi-Long Wu, Vera Hirsh, et al.
Targeted Oncology|February 8, 2023
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.
Histopathology|October 22, 2024
Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)Wendy A Cooper, Fleur Webster, Kelly J Butnor, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Pageof 28

Showing results (141-150 of 273) with videos related to

Sort By:
Pageof 28
Frontiers in Oncology|May 16, 2022
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: An Updated Database of 1023 Cases Brief ReportJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.
JTO Clinical and Research Reports|September 30, 2021
Biomarker Testing for People With Advanced Lung Cancer in EnglandJana B Adizie, Judith Tweedie, Aamir Khakwani, et al.
Cancers|January 26, 2024
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint BlockadeAndriani Charpidou, Grigorios Gerotziafas, Sanjay Popat, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
Targeted Oncology|January 18, 2023
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.
Plos One|October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatmentsAnna Minchom, Parames Thavasu, Zai Ahmad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2016
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesMartin Schuler, Yi-Long Wu, Vera Hirsh, et al.
Targeted Oncology|February 8, 2023
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.
Histopathology|October 22, 2024
Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)Wendy A Cooper, Fleur Webster, Kelly J Butnor, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Pageof 28